TPBG (US11008399B2 Biosimilar) Recombinant Monoclonal Antibody
-
貨號(hào):CSB-RA024093MB1HU
-
規(guī)格:¥83486
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:TPBG (US11008399B2 Biosimilar Antibody) 重組單克隆抗體是一種針對(duì)滋養(yǎng)層糖蛋白(TPBG),其靶點(diǎn)TPBG存在多個(gè)別名,包括5T4癌胚抗原、5T4癌胚滋養(yǎng)層糖蛋白、T4癌滋養(yǎng)層糖蛋白、M6P1、Wnt激活抑制因子1(WAIF1)等。該抗體以重組人TPBG蛋白制備,具有明確的抗原特異性,種屬反應(yīng)性覆蓋人類和恒河猴(Macaca mulatta),為相關(guān)研究提供了可靠的工具支持。 靶向TPBG抗體的類似物作為一種針對(duì)在多種腫瘤中高表達(dá)的癌胚抗原的治療手段,已成為抗腫瘤治療的潛在方向。研究表明,此類藥物通過特異性結(jié)合TPBG,抑制腫瘤細(xì)胞信號(hào)通路(如Wnt通路)或介導(dǎo)抗體依賴的細(xì)胞毒性作用(ADCC),從而達(dá)到抗腫瘤效果。目前,針對(duì)TPBG類似物已進(jìn)入早期臨床試驗(yàn)階段,評(píng)估其在晚期實(shí)體瘤患者中的安全性、藥代動(dòng)力學(xué)特征及初步療效,為后續(xù)治療方案優(yōu)化奠定基礎(chǔ)。 該重組單克隆抗體憑借對(duì)人類和恒河猴TPBG的交叉反應(yīng)性,廣泛應(yīng)用于腫瘤生物學(xué)機(jī)制研究和藥物研發(fā)。在基礎(chǔ)研究中,可通過實(shí)驗(yàn),檢測(cè)TPBG在正常組織與腫瘤組織中的表達(dá)差異,探究其在腫瘤發(fā)生發(fā)展中的分子機(jī)制;在藥物開發(fā)中,可用于篩選和驗(yàn)證TPBG靶向藥物的結(jié)合活性、特異性及體外抗腫瘤效果,同時(shí)支持恒河猴等非人靈長(zhǎng)類動(dòng)物模型的藥效學(xué)和毒理學(xué)研究,加速藥物從實(shí)驗(yàn)室到臨床的轉(zhuǎn)化進(jìn)程。此外,該抗體還為構(gòu)建TPBG基因敲除或過表達(dá)細(xì)胞模型、建立腫瘤異種移植模型等提供了關(guān)鍵工具,助力深入解析TPBG的生理功能及臨床轉(zhuǎn)化價(jià)值。
-
Uniprot No.:
-
基因名:
-
別名:Trophoblast glycoprotein; 5T4 oncofetal antigen; 5T4 oncofetal trophoblast glycoprotein; T4 oncotrophoblast glycoprotein; M6P1; Wnt-activated inhibitory factor 1; WAIF1; TPBG; 5T4
-
反應(yīng)種屬:Human
-
免疫原:Recombinant Human TPBG protein
-
免疫原種屬:Homo sapiens (Human)
-
標(biāo)記方式:Non-conjugated
-
克隆類型:Monoclonal
-
濃度:It differs from different batches. Please contact us to confirm it.
-
保存緩沖液:0.01M PBS,pH7.4
-
產(chǎn)品提供形式:Liquid
-
應(yīng)用說明:Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method. -
儲(chǔ)存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:In stock
-
用途:It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
相關(guān)產(chǎn)品
靶點(diǎn)詳情
-
功能:May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a-dependent LRP6 internalization.
-
基因功能參考文獻(xiàn):
- In extravillous trophoblasts, 5T4 may function in epithelial-to-mesenchymal transition during placentation. The role of syncytiotrophoblast 5T4 is unknown, but its abundance in shed syncytial vesicles may signify route of sensitization of the maternal immune system. PMID: 28481180
- Collectively, these findings demonstrate that an anti-5T4 antibody-drug conjugate reduces the fraction of cancer stem cells (CSC), and prevents local recurrence and suggest a novel therapeutic approach for patients with head and neck squamous cell carcinoma. PMID: 27780858
- We obtained GWS evidence (P < 2.7 x 10(-6)) for gene-based association in the total sample with a novel locus, TPBG (P = 1.8 x 10(-6)). PMID: 28183528
- In conclusion, the present study provided evidence that TPBG is involved in PDAC metastasis, and that TPBG and its associated signaling pathways may be a suitable target for pancreatic ductal adenocarcinoma therapy. PMID: 25738465
- 5T4 expression is mechanistically associated with the directional movement of cells through epithelial mesenchymal transition, facilitation of CXCL12/CXCR4 chemotaxis, blocking of canonical Wnt/beta-catenin while favouring non-canonical pathway signalling PMID: 25066861
- Tyrosine 325 plus the leucine-rich repeat 1 surface centered on a second exposed aromatic residue, phenylalanine 97, are essential for inhibition of Wnt/beta-catenin signaling. PMID: 24582434
- The surface expression of 5T4 marks the use of the CXCR4 rather than the CXCR7 receptor, with distinct consequences for CXCL12 exposure. PMID: 22956548
- 5T4 is a potential new antigen for targeted therapies such as immunotherapy in MPM, as it is overexpressed on mesothelioma cells and recognised by 5T4-specific cytotoxic T-cells. PMID: 22498111
- Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen PMID: 11903056
- Results sugest that 5T4 is a transient marker of human embryonic stem cell differentiation & that 5T4 phenotype, colony seeding density and culture conditions influence the maintenance of pluripotent hES cells and their differentiation to neural lineages. PMID: 16616918
- there is a repertoire of CD8 T cell recognition of 5T4 in normal human donors and some candidate HLA-A*0201 epitopes have been identified PMID: 16646078
- the mRNA expression of trophoblast glycoprotein is up-regulated in cells circulating within blood from women with preeclampsia. PMID: 17978129
- 5T4-based cancer vaccine: cytotoxic T lymphocyte epitopes identified in Trovax-vaccinated colorectal cancer patients PMID: 18567615
- colorectal cancer patients who had preexisting cell proliferative responses to 5T4 were longer-term survivors PMID: 18833005
顯示更多
收起更多
-
亞細(xì)胞定位:Cell membrane; Single-pass type I membrane protein.
-
組織特異性:Expressed by all types of trophoblasts as early as 9 weeks of development. Specific for trophoblastic cells except for amniotic epithelium. In adult tissues, the expression is limited to a few epithelial cell types but is found on a variety of carcinoma.
-
數(shù)據(jù)庫鏈接:
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-















